Leverage scientific, clinical, and regulatory expertise to de-risk drug development, from the outset
Follow the most efficient regulatory pathway by proactively addressing all facets of drug development. By understanding the intricacies of scientific, clinical and regulatory requirements, you can identify any potential risks earlier, and implement appropriate mitigation strategies.
In the early phases of product development, our global team of ex-regulators and industry specialists provide:
Regulatory intelligence
Regulatory intelligence is a prerequisite to stay informed about the evolving global regulatory landscape. We remain fully up-to-date with the latest changes to FDA and EMA regulations and guidelines, to support our clients to enhance their drug development strategies and navigate the complexities of regulatory requirements, from the early stages of development.
Strategic regulatory advice
With tailored approaches for asset development, from bench to patient, we utilize our teams’ expertise and regulatory intelligence to develop robust regulatory strategies that align with current best practices, including Good Clinical Practice (GCP). Our goal is to enable clients to make informed decisions, navigate the evolving regulatory environment and achieve successful drug development outcomes.
Regulatory authority/agency consulting and engagement
We understand the critical importance of creating a positive first impression with regulatory authorities, with early and frequent engagement. By formulating an optimal approach to engage with authorities, our team of ex-regulators can navigate their expectations and requirements.
Regulatory gap assessment
With comprehensive regulatory gap assessment services, our team evaluates clinical, non-clinical and CMC data, comparing it with national and international regulatory requirements and guidelines. We proactively engage with authorities to check the suitability of existing data, proposed clinical studies and forthcoming marketing approvals with the aim of:
- Identifying any gaps in data
- Defining crucial points for discussions with regulatory authorities
- Establishing a solid foundation for the development plan of your product
Target product profile (TPP) consulting
Define the TPP for your product with guidance on considerations including intended use, patient population, desired efficacy and safety profile, dosage form and route of administration.
Product development plans
With a track record of delivering well-crafted and accurate product development plans, we provide comprehensive support across non-clinical, CMC, and clinical development. Our expertise spans the drug development continuum including study design, regulatory compliance, protocol development, and patient recruitment so we understand the criticality of getting it right. By leveraging our holistic approach, we aim to minimize risk and optimize the potential for success so your product development plan aligns with regulatory requirements and your corporate goals.
A trusted partner
Our dedication to patients and the pursuit of safe and effective drug development is our purpose. With a team of 1,300+ regulatory specialists, including former regulators from agencies across the world, Parexel has the knowledge, insights and technology-enabled processes to accelerate and streamline your drug development journey. With experience in more than 110 countries, we provide strategic regulatory advice, proactively identify and mitigate risks and navigate the ever-evolving regulatory landscape. Our deep therapeutic insight and proven track record make us a reliable partner for achieving regulatory success.
Our experts
Mwango Kashoki, M.D., M.P.H.
Senior Vice President, Global Head of Regulatory Strategy
Kurt Brorson, Ph.D.
Vice President, Technical
Sinan Sarac, M.D., Ph.D., M.Sc.
Senior Vice President, Head, Regulatory Strategy Europe
Pengfei Song, Ph.D.
Vice President, Regulatory Strategy
Aaron Sosa, M.D.
Vice President, Technical SME Oncology, Regulatory Strategy
Bernardo Haddock Lobo Goulart, M.D.
Vice President - Technical, Regulatory Strategy
Our experts
Mwango Kashoki, M.D., M.P.H.
Senior Vice President, Global Head of Regulatory Strategy
Kurt Brorson, Ph.D.
Vice President, Technical
Sinan Sarac, M.D., Ph.D., M.Sc.
Senior Vice President, Head, Regulatory Strategy Europe
Pengfei Song, Ph.D.
Vice President, Regulatory Strategy
Aaron Sosa, M.D.
Vice President, Technical SME Oncology, Regulatory Strategy
Bernardo Haddock Lobo Goulart, M.D.
Vice President - Technical, Regulatory Strategy
The Regulatory Navigator
Want to hear from our experts on the latest industry topics? Visit our Insights Center to read, watch, and listen.
Related Insights
Article
Regulation pathway/strategy: Key considerations for foreign medical product registration in China
Jul 1, 2025
Blog
RNA-based therapies: Aligning CMC strategies with “borrowed” FDA regulatory guidance
Jun 30, 2025
Blog
FDA’s new priority voucher review program: Potential implications and next steps for sponsors
Jun 20, 2025
Blog
Traceability, proportionality, and flexibility: Strategies for operationalizing ICH E6(R3)
Jun 17, 2025
Manufacturing and control strategies for Cell and Gene Therapy products: Navigating EU and US regulatory requirements
Jun 12, 2025
Blog
Optimize your CMC strategy: Five steps to avoid regulatory setbacks
May 15, 2025
Webinar
Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development
May 6, 2025
Blog
FDA guidances for development of oligonucleotide therapeutics: Key takeaways for sponsors
May 5, 2025
Blog
Advancing the transition from animal models to alternative methods: FDA's initiative and sponsors' opportunities
May 1, 2025
Whitepaper
Biosimilar development: Optimizing PK/PD studies
Mar 28, 2025
Webinar
Navigating Clinical Trials in Japan: From Regulatory Strategy to Operational Success
Mar 28, 2025
Blog
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Mar 17, 2025
Blog
Streamlining orally inhaled product (OIP) development with EMA’s new guideline – the clinical perspective
Mar 17, 2025
Blog
Accelerated approval: Navigating FDA’s recent guidance and confirmatory trial considerations
Mar 6, 2025
Blog
Regulatory strategies for ADCs
Feb 28, 2025
Playbook
Streamlining development in the EU: Strategies for smoother CTA submissions
Feb 27, 2025
Playbook
Streamlining success: How integrated evidence planning transforms asset development
Feb 27, 2025
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Webinar
Maintain EU-CTR compliance: Guidance on the first substantial modification after slim transition and ongoing strategic information management
Feb 3, 2025
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Related Insights
Article
Regulation pathway/strategy: Key considerations for foreign medical product registration in China
Jul 1, 2025
Blog
RNA-based therapies: Aligning CMC strategies with “borrowed” FDA regulatory guidance
Jun 30, 2025
Blog
FDA’s new priority voucher review program: Potential implications and next steps for sponsors
Jun 20, 2025
Blog
Traceability, proportionality, and flexibility: Strategies for operationalizing ICH E6(R3)
Jun 17, 2025
Manufacturing and control strategies for Cell and Gene Therapy products: Navigating EU and US regulatory requirements
Jun 12, 2025
Blog
Optimize your CMC strategy: Five steps to avoid regulatory setbacks
May 15, 2025
Webinar
Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development
May 6, 2025
Blog
FDA guidances for development of oligonucleotide therapeutics: Key takeaways for sponsors
May 5, 2025
Blog
Advancing the transition from animal models to alternative methods: FDA's initiative and sponsors' opportunities
May 1, 2025
Whitepaper
Biosimilar development: Optimizing PK/PD studies
Mar 28, 2025
Webinar
Navigating Clinical Trials in Japan: From Regulatory Strategy to Operational Success
Mar 28, 2025
Blog
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Mar 17, 2025
Blog
Streamlining orally inhaled product (OIP) development with EMA’s new guideline – the clinical perspective
Mar 17, 2025
Blog
Accelerated approval: Navigating FDA’s recent guidance and confirmatory trial considerations
Mar 6, 2025
Blog
Regulatory strategies for ADCs
Feb 28, 2025
Playbook
Streamlining development in the EU: Strategies for smoother CTA submissions
Feb 27, 2025
Playbook
Streamlining success: How integrated evidence planning transforms asset development
Feb 27, 2025
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Webinar
Maintain EU-CTR compliance: Guidance on the first substantial modification after slim transition and ongoing strategic information management
Feb 3, 2025
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025